Perspective from Robert Bucelli, MD, PhD Dr. Robert Bucelli is a professor and neurologist at Washington University in St. Louis. He consults and cares for many people with ALS at the school’s world-renowned ALS Center. Dr. Bucelli is a paid consultant for Biogen and was compensated for this article.
EKZ-102, Eikonizo Therapeutics‘s experimental oral therapy for amyotrophic lateral sclerosis (ALS), is on track to enter early clinical testing in 2026, according to an announcement from the company. EKZ-102 is designed to block the activity of a protein called HDAC6. A team led by scientists at Eikonizo…
Last week, my husband, Todd, celebrated his 55th birthday — a milestone we never anticipated after he was diagnosed with ALS at age 39 in June 2010. For his 40th birthday that October, I asked friends and family to send me pictures and their favorite memories with Todd, and…
Once in a while, there’s a topic on the ALS News Today Forums that inspires a new column. The question posted was a simple one: “Do you celebrate ALS-related anniversaries?” I intended my reply to be just a simple “Yes.” But I ended up adding, “However, what I…
Life Time will host a nationwide fitness event Oct. 25 to raise funds for ALS research and children’s health. The annual GO90: Move with Meaning challenge will take place at Life Time locations nationwide on Oct. 25 at 9 a.m. local time. Life Time members and nonmembers are…
It took time for Philip to discover acceptance was key to him for living with ALS. Learn about his journey from diagnosis to getting the help he needed to move ahead. This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any…
People with a history of traumatic brain injury (TBI) have a nearly three times higher risk of developing amyotrophic lateral sclerosis (ALS) than those who have not experienced a head injury, a new study found. However, the risk is highest in the two years following a TBI and decreases…
Using seven clinical measures that are fairly easy to assess, researchers have developed a machine learning model to help predict mortality in people with amyotrophic lateral sclerosis (ALS), according to a study. The model, which was trained on data from more than 1,900 patients, may aid clinicians and families…
“What do you think about having one thimbleberry design on one side of a mug and a different one on the other?” I asked my husband, Todd. We’d been brainstorming ideas for some print-on-demand items that I might try selling. Todd has had a fixed income ever since he was…
A pivotal Phase 3 clinical trial testing the oral therapy pridopidine in people with amyotrophic lateral sclerosis (ALS) is expected to start in January, following promising results seen in the HEALEY ALS platform trial. Pending regulatory clearance, enrollment will begin at ALS treatment centers in the U.S., Canada,…
